Genevieve Neal-Perry, MD, PhD

ACOG 2026: Genevieve Neal-Perry, MD, discussed her clinical experience with elinzanetant for the treatment of VMS associated with menopause.

Genevieve Neal-Perry, MD, PhD, outlines unmet needs in managing vasomotor symptoms among African American women and discusses how elinzanetant (Lynkuet) may help shape more equitable care.

Genevieve Neal-Perry, MD, PhD, discusses how elinzanetant (Lynkuet) improves sleep quality and menopause-related quality of life through its dual neurokinin receptor antagonism.

Genevieve Neal-Perry, MD, PhD, explains how rapid onset of symptom relief with elinzanetant (Lynkuet) may improve patient satisfaction and adherence.

Genevieve Neal-Perry, MD, PhD, reviews the design and pooled efficacy results of the OASIS 1 and OASIS 2 trials evaluating elinzanetant (Lynkuet) for moderate to severe vasomotor symptoms.

Genevieve Neal-Perry, MD, PhD, discusses the profound impact of vasomotor symptoms on quality of life during menopause and highlights racial disparities that disproportionately affect African American women.